Objectives: Over-prescription of postoperative opioid medication is a major contributor to the current opioid abuse epidemic in the United States. Current research into prescribing practices has suggested patients be limited to seven days or <200 oral morphine equivalents (OME) following surgical procedures. Our aim was to identify patterns of postoperative opioid prescribing for common vascular procedures.
Objectives: Over-prescription of postoperative opioid medication is a major contributor to the current opioid abuse epidemic in the United States. Current research into prescribing practices has suggested patients be limited to seven days or <200 oral morphine equivalents (OME) following surgical procedures. Our aim was to identify patterns of postoperative opioid prescribing for common vascular procedures.
Methods: Nine surgical and endovascular modules within the Vascular Quality Initiative (VQI) from 2015 to 2017 were queried across an integrated health system. Discharge opioid prescriptions were converted to OME and dichotomized as top-quartile versus lower three quartiles within each procedure type among opioid naïve patients. Multivariable logistic regression analysis identified factors associated with top quartile prescriptions and 30-day refills.
Results: Among 1546 opioid naïve patients, 739 (48%) received a discharge opioid prescription; median OME was 0 (interquartile range [IQR] , 0-150), and 349 (23%) had >200 OME. Among those with a discharge prescription, median OME was 180 (IQR, . OME varied by procedure (P < .001), with highest OME after suprainguinal bypass (median, 225) and infrainguinal bypass (200) and lowest after carotid artery stent, carotid artery endarterectomy, and percutaneous peripheral vascular intervention (all medians of 0; Fig) . Discharge OME >200 varied significantly between medical center, ranging from 18% of discharge prescriptions at Hospital A to 36% and 34% of prescriptions at Hospitals B and C (P < .001). On multivariable analysis, younger patient age (<65 years old vs 80 years old, odds ratio [OR], 2.9, P < .001), procedure-specific top quartile duration of stay (OR, 1.6; P ¼ .007), and prior tobacco use (OR, 1.9; P ¼ .002) were associated with higher odds of top quartile prescriptions at discharge. Sex, body mass index and preoperative American Society of Anesthesiologists (ASA) classification were not associated with high OME at discharge. Age <65 versus 80 (OR, 2.2; P ¼ .02), later treatment year (2017 vs 2015 OR 2.8; P ¼ .002), dialysis (OR, 2.5; P ¼ .02) and ASA 1-2 vs 4-5 (OR, 4.0; P ¼ .03) were all associated with increased likelihood of opioid refills postdischarge. OME >200 at discharge was not associated with opioid refills.
Conclusions: Opioid prescriptions at discharge vary with the invasiveness of vascular surgical procedures. Less than 25% of patients receive >200 OME. Variation by center represents a lack of standardization in prescribing practices and an opportunity for further improvement.
Patient factors and procedure type can alert clinicians to patients at risk of higher than recommended OME. Patients with high OME at discharge do not refill at higher rates. Objectives: With advances in endovascular technology pararenal abdominal aortic aneurysms (pAAA) may be treated with fenestrated endovascular aneurysm repair (FEVAR). Although the length of hospital stay is shorter compared with open surgical repair (OSR) reintervention rates and need for ongoing surveillance may lead to long-term higher costs. The goal of this study was to evaluate the long-term cost-effectiveness of FEVAR and OSR for elective pAAA repair.
Methods: Using a Markov model we evaluated costs from the societal perspective using Medicare reimbursements in 2017 US dollars and Quality Adjusted Life Years (QALYs) to calculate the incremental cost-effectiveness ratio (ICER) between the two surgical strategies. Published literature regarding short-term and long-term clinical outcomes of FEVAR and OSR were used to evaluate re-interventions rates, follow-up imaging practices and complications after a procedure leading to chronic complications such as hemodialysis, myocardial infarction, and stroke. Studies regarding infrarenal AAA were imputed if data regarding pAAA was unavailable. Sensitivity analysis was performed on model input variables with high uncertainty. Results: Our model found an incremental cost of $6360 and incremental QALY of 0.30 with elective FEVAR resulting in an incremental costeffectiveness ratio (ICER) of $21,200 per QALY. The probability of patients who required hemodialysis as a complication of FEVAR, cost of FEVAR and OSR, as well as re-intervention rates after FEVAR had the greatest significant effects on the ICER. A tornado diagram shows variables affecting the ICER with the largest effect from the top (Fig) .
Conclusions: Our analysis indicates that although overall FEVAR costs may be higher, the QALY gained makes it a cost-effective treatment for pAAA. However, limitations in the primary data and individual patient factors preclude definitive assessment and broad validation. 
